Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the ...
Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KCNQ2-EE Patients Expected to be Initiated in Mid-2019 Conference Call Today at 8:00 am ET Xenon to Webcast Update on Epilepsy Pipeline from Biocentury NewsMakers Conference on September 7, 2018 …